Board Meeting18 May 2026, 03:14 pm
Bal Pharma Board Meeting on May 27, 2026 to Consider Audited Results
AI Summary
Bal Pharma Ltd has scheduled a Board of Directors meeting on May 27, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board will also consider recommending a dividend, if any, for the financial year ended March 31, 2026, and appoint Internal Auditors & Cost Auditors for F.Y 2025-26. Additionally, the board will approve the grant of stock options to employees under the “Bal Pharma Ltd — Employee Stock Option Plan -2025”. The trading window for dealing in the company's securities has been closed from April 1, 2026, until the close of business hours on May 29, 2026.
Key Highlights
- Board to approve audited financial results for FY26 on May 27, 2026.
- Dividend recommendation to be considered for FY26.
- Appointment of Internal & Cost Auditors for F.Y 2025-26 is on the agenda.
- Approval of employee stock options under ESOP 2025 is scheduled.
- Trading window closed until May 29, 2026, post results declaration.
Price Impact
More from BALPHARMA